Pharmaceutical compositions for oral administration
AssigneeXenon Pharmaceuticals Inc.
InventorsConrad Stewart Winters, Shaun Lee Gammill
Life of this patent
Estimating the term…
Abstract
This invention is directed to pharmaceutical compositions for oral administration to a mammal, wherein the pharmaceutical compositions comprise a spiro-oxindole compound, as a single stereoisomer or as a mixture thereof, or a pharmaceutically acceptable salt thereof. These pharmaceutical compositions are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
Claims25
A pharmaceutical composition for oral administration to a mammal comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):
- as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition for oral administration to a mammal comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):
- as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof;
- wherein the spiro-oxindole compound is present in a concentration of from about 0.1% w/w to about 25% w/w, wherein a first pharmaceutically acceptable excipient is Labrasol® and is present in a concentration of from about 35% w/w to about 65% w/w, wherein a second pharmaceutically acceptable excipient is Gelucire® 44/14 and is present in a concentration of from about 25% w/w to about 45% w/w, and wherein a third pharmaceutically acceptable excipient is propylene glycol and is present in a concentration of from about 1.0% w/w to about 10% w/w.
A pharmaceutical composition for oral administration to a mammal comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):
- as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof;
- wherein the spiro-oxindole compound is present in an unit dosage amount of between about 5 mg and about 100 mg, wherein a first pharmaceutically acceptable excipient is Labrasol® and is present in a concentration of from about 35% w/w to about 65% w/w, wherein a second pharmaceutically acceptable excipient is Gelucire® 44/14 and is present in a concentration of from about 25% w/w to about 45% w/w, and wherein a third pharmaceutically acceptable excipient is propylene glycol and is present in a concentration of from about 1.0% w/w to about 10% w/w.
A method of treating a sodium channel-mediated disease or condition in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):
- as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.
A method of treating pain through inhibition of ion flux through a voltage-dependent sodium channel in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):
- as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.
A method of treating benign prostatic hyperplasia in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):
- as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.
A method of treating pruritis in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):
- as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.
A method of treating cancer in a mammal, wherein the methods comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):
- as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.